MK-8291
Phase 1Small molecule
Merck & Co.MK-8291 is one of 36 small molecule programs targeting Neuralgia. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Neuralgia
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cymbalta
Alnylam PharmaceuticalsApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Fycompa
CCatalyst Biosciences
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Neurontin
VViatris Specialty LLC
Phase 3
Aptiom
Sumitomo Pharma America, Inc.Phase 3
Dolophine
HHikma Pharmaceuticals LLC
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-8291. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company